The pharmaceutical state-owned company PT Indofarma (INAF) is reportedly going to sell the Covid-19 drug Desrem, an antiviral in the form of a lyophilized injection powder containing the active ingredient remdesivir next week.
President Director of Indofarma Arief Pramuhanto confirmed the news. When contacted by Liputan6.com, he stated that the launch of this drug would be carried out next week. The price itself will be released on Monday (5/10).
"Yes, next week, we will release the price tomorrow Monday," said Arief, Sunday (4/10).
Even though, Arief could not specify the exact price range of the drug, the amount of the medicine and the accessibility of the public to get the medicine (whether it is sold freely or not).
Previously, Kalbe Farma also sold the Covid-19 drug remdesivir, Covifor. Initially, the price of the Covid-19 drug remdesivir Covifor, produced by Hetero India, imported by Amarox and marketed and distributed by Kalbe Farma, was set at Rp 3 million per vial. After the adjustment, it is now Rp. 1.5 million per vial.
This drug price adjustment sees several conditions, including the development of the COVID-19 case and the need for this drug.
"After a joint discussion between Kalbe, Hetero India and Amarox, we agreed to provide a special selling price for Covifor," Vidjongtius, President Director of PT Kalbe Farma Tbk in his statement.
Reporter: Athika Rahma